1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2009-03, NCT00868569
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2009-04, NCT00874406
|
|
3.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12154, NCT01438112
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-004405-25, NCT01683864
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: NCRI-ACT-II, EU-20056, UKCCCR-ACT-II, ISRCTN26715889, NCT00025090
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: T1303, NCT00201396
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2008-46, NCT00643877
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 102.1, NCT00384891
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: LCI-THALIDOMIDE, LCI-09-06-15, NCT00921531
|
|
10.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1208, E1208, NCT01004978
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CRC-TU-BL3010-HYMN, CRCTU-BL3010-HYMN, ISRCTN85785327, EUDRACT-2008-005428-99, EU-21015, UCL-08/0365, KYOWA-CRC-TU-BL3010-HYMN, MREC-09/H0717/56, NCT01094964
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EN3348-303, NCT01200992
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: HCC008010, NCT01229839
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: HCC2011A, NCT01259414
|
|
15.
|
Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N10CB, N10CB, NCT01473290
|
|
16.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: A.1459/2011, NCT01579591
|
|
17.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: FinnBladder 9, 2012-000559-15, NCT01675219
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: J1070, RC2CA148346-01, NA_00032826, NCT01296763
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FFCD 0904, NCT01581840
|
|
20.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG 276, NCT01671488
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 20 to 70 Sponsor: Other Protocol IDs: WUCC-0701, NCT00454519
|
|
22.
|
Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GI-24329, NCT00754078
|
|
23.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UMDNJ-20090859, 20090859, BAYER-IST000477, NCT00949182
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: STU 12339, P30CA060553, STU# 00012339, CDR0000651416, NU-09I2, IRB# STU00012339, NCT00956930
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0926, RTOG-0926, NCT00981656
|